Even though the tumor biology and prognosis of patients with concomitant KRAS and BRAF mutations have been still uncertain, previous research suggests that these concomitant mutations are associated with tumor progression such as lymph node metastasis and higher T stage [25,27]. This evidence concerns the gene BRAF and neoplasm.